Symbols

DRUG

Bright Minds·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About DRUG

Bright Minds Biosciences Inc.

A biotech company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain

Industry

Biological Technology

Established Date

05/31/2019

Listing Date

11/08/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

09-30

Website

www.brightmindsbio.com

Security Type

Common stock

Office address

400 N Aberdeen St Suite 900 Chicago IL 60642

Business

Introduction

Bright Minds Biosciences Inc., was incorporated on May 31, 2019 under the British Columbia Business Companies Act. The company is a biotechnology company that develops innovative therapies to improve the lives of people with severe and life-changing neurological and psychiatric disorders. The Bright Minds pipeline includes novel compounds targeting key receptors in the brain to address diseases with high unmet medical needs, including epilepsy, depression and other central nervous system (CNS) diseases. The company focuses on delivering breakthrough therapies that transform patients' lives. The company has developed a unique highly selective serotonergic agonist platform that exhibits selectivity on different serotonergic receptors. This provides a rich portfolio of Novel Chemical Entities (NCE) projects in the fields of Neurology and Psychiatry.

Company Financials

EPS

DRUG has released its 2024 Q1 earnings. EPS was reported at -0.44, versus the expected 0, missing expectations. The chart below visualizes how DRUG has performed over recent quarters, highlighting trends in earnings surprises.